AzTrials
AzTrials

Relapsing Multiple SclerosisPhase 3NCT04338061

Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

A Phase 3 study testing Teriflunomide and Evobrutinib in people with Relapsing Multiple Sclerosis, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany at 278 sites in 32 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Read more about this study

Who is it for?
Ages 18 to 55 years
Conditions the study is for
Relapsing Multiple Sclerosis
What is being tested?
Teriflunomide and Evobrutinib
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,166 participants
Where
278 sitesin 32 countries
Study dates
2 Jul 2020to 19 Mar 2024
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 55 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Participants are diagnosed with RMS (relapsing-remitting multiple sclerosis [RRMS] or secondary progressive multiple sclerosis [SPMS] with relapses) in accordance with 2017 Revised McDonald criteria (Thompson 2018)
  • Participants with one or more documented relapses within the 2 years before Screening with either: a. one relapse which occurred within the last year prior to randomization, OR b. the presence of at least 1 gadolinium-enhancing (Gd+) T1 lesion within 6 months prior to randomization
  • Participants have Expanded Disability Status Scale (EDSS) score of 0 to 5.5 at Screening and Baseline (Day 1). Participants with an EDSS score less than or equal to [<=] 2 at Screening and Baseline (Day 1) are only eligible for participation if their disease duration (time since onset of symptoms) is no more than 10 years
  • Participants are neurologically stable for >= 30 days prior to both screening and baseline (Day 1)
  • Female participants must be neither pregnant nor breast-feeding or must lack child-bearing potential (as defined by either: post-menopausal or surgically sterile), or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
  • Male participants must refrain from donating sperm and/or abstain from intercourse with women of child-bearing potential or use an effective method of contraception for the duration of the study and at least 2 years after study intervention due to the long elimination period for teriflunomide of 2 years, unless the participant undergoes an accelerated elimination procedure
  • Participants have given written informed consent prior to any study-related procedure
  • Other protocol defined inclusion criteria could apply.

Who cannot join

  • Participants diagnosed with Progressive MS, in accordance with the 2017 Revised McDonald criteria as follows: a). Participants with Primary Progressive MS. b) Participants with secondary progressive MS without evidence of relapse
  • Disease duration more than (>) 10 years in participants with an EDSS =< 2.0 at screening and Baseline (Day 1)
  • Immunologic disorder other than MS, or any other condition requiring oral, intravenous (IV), intramuscular, or intra-articular corticosteroid therapy, with the exception of well-controlled Type 2 diabetes mellitus or well controlled thyroid disease
  • Other protocol defined exclusion criteria could apply.

Trial locations and contacts

278 sites in 32 countries.

278 sites in 32 countries

United States38 sites
  • Research Site 746

    Altamonte Springs, Florida, 32714

  • Research Site 724

    Amherst, New York, 14226

  • Research Site 736

    Asheville, North Carolina, 28006

  • Research Site 711

    Canton, Ohio, 44735

  • Research Site 712

    Chapel Hill, North Carolina, 27599

  • Research Site 759

    Colorado Springs, Colorado, 80907

  • Research Site 757

    Columbus, Ohio, 43214

  • Research Site 752

    Cullman, Alabama, 35058

  • Research Site 734

    Dayton, Ohio, 45459

  • Research Site 738

    Detroit, Michigan, 48202

  • Research Site 715

    Evanston, Illinois, 60201

  • Research Site 725

    Fort Collins, Colorado, 80528

  • Research Site 714

    Fort Wayne, Indiana, 46804

  • Research Site 751

    Hanford, California, 93230

  • Research Site 742

    Honolulu, Hawaii, 96817

  • Research Site 718

    Jacksonville, Florida, 32209

  • Research Site 744

    Lafayette, Indiana, 47904

  • Research Site 702

    Naples, Florida, 34105

  • Research Site 735

    Nicholasville, Kentucky, 40356

  • Research Site 721

    Norfolk, Virginia, 23502

  • Research Site 740

    Orlando, Florida, 32806

  • Research Site 717

    Overland Park, Kansas, 66212

  • Research Site 748

    Philadelphia, Pennsylvania, 19107

  • Research Site 726

    Port Charlotte, Florida, 33952

  • Research Site 730

    Raleigh, North Carolina, 27607

  • Research Site 703

    San Antonio, Texas, 78258

  • Research Site 719

    Sarasota, Florida, 34243

  • Research Site 706

    Scarborough, Maine, 04074

  • Research Site 741

    Scottsdale, Arizona, 85258

  • Research Site 723

    St Louis, Missouri, 63128

  • Research Site 743

    Tampa, Florida, 33612

  • Research Site 707

    Tampa, Florida, 33634

  • Research Site 704

    Tucson, Arizona, 85710

  • Research Site 732

    Vero Beach, Florida, 32960

  • Research Site 705

    Weeki Wachee, Florida, 34607

  • Research Site 737

    West Hollywood, California, 90048

  • Research Site 753

    West Palm Beach, Florida, 33407

  • Research Site 728

    Winston-Salem, North Carolina, 27157

Other trials in United States

Russia23 sites
  • Research Site 325

    Kazan'

  • Research Site 329

    Kazan'

  • Research Site 323

    Kemerovo

  • Research Site 344

    Kirov

  • Research Site 340

    Krasnodar

  • Research Site 334

    Krasnoyarsk

  • Research Site 341

    Moscow

  • Research Site 343

    Moscow

  • Research Site 345

    Moscow

  • Research Site 332

    Nizhny Novgorod

  • Research Site 327

    Novosibirsk

  • Research Site 330

    Novosibirsk

  • Research Site 331

    Novosibirsk

  • Research Site 335

    Novosibirsk

  • Research Site 328

    Rostov-on-Don

  • Research Site 324

    Saint Petersburg

  • Research Site 338

    Saint Petersburg

  • Research Site 339

    Saint Petersburg

  • Research Site 342

    Saint Petersburg

  • Research Site 346

    Saint Petersburg

  • Research Site 326

    Saransk

  • Research Site 321

    Sestroretsk

  • Research Site 337

    Tyumen

Other trials in Russia

Ukraine23 sites
  • Research Site 415

    Chernihiv

  • Research Site 417

    Chernihiv

  • Research Site 414

    Dnipro

  • Research Site 416

    Dnipro

  • Research Site 420

    Dnipro

  • Research Site 413

    Ivano-Frankivsk

  • Research Site 624

    Kharkiv

  • Research Site 632

    Kharkiv

  • Research Site 633

    Kharkiv

  • Research Site 419

    Kherson

  • Research Site 411

    Kyiv

  • Research Site 418

    Kyiv

  • Research Site 629

    Lutsk

  • Research Site 627

    Lviv

  • Research Site 622

    Poltava

  • Research Site 625

    Rivne

  • Research Site 628

    Ternopil

  • Research Site 630

    Uzhhorod

  • Research Site 623

    Vinnytsia

  • Research Site 412

    Zaporizhzhya

  • Research Site 621

    Zaporizhzhya

  • Research Site 631

    Zaporizhzhya

  • Research Site 626

    Zhytomyr

Other trials in Ukraine

Poland19 sites
  • Reserach Site 267

    Bydgoszcz

  • Reserach Site 268

    Bydgoszcz

  • Research Site 273

    Katowice

  • Research site 846

    Katowice

  • Research site 274

    Katowice-Ochojec

  • Research Site 276

    Krakow

  • Research Site 263

    Lodz

  • Research Site 272

    Lodz

  • Research Site 266

    Nowa Sól

  • Research Site 270

    Poznan

  • Research Site 262

    Rzeszów

  • Research Site 265

    Siemianowice Śląskie

  • Research Site 271

    Szczecin

  • Research Site 264

    Warsaw

  • Research Site 277

    Warsaw

  • Reserach Site 275

    Warsaw

  • Research Site 269

    Wroclaw

  • Research Site 261

    Zabrze

  • Research Site 278

    Zamość

Other trials in Poland

Bulgaria16 sites
  • Research Site 155

    Blagoevgrad

  • Research Site 156

    Dupnitsa

  • Research Site 157

    Pleven

  • Research Site 801

    Pleven

  • Research Site 804

    Pleven

  • Research Site 805

    Plovdiv

  • Research Site 151

    Sofia

  • Research Site 152

    Sofia

  • Research Site 153

    Sofia

  • Research Site 158

    Sofia

  • Research Site 159

    Sofia

  • Research Site 160

    Sofia

  • Research Site 802

    Sofia

  • Research Site 803

    Sofia

  • Research Site 808

    Sofia

  • Research Site 154

    Veliko Tarnovo

Other trials in Bulgaria

Greece15 sites
  • Research Site 194

    Athens

  • Research Site 196

    Athens

  • Research Site 197

    Athens

  • Research Site 201

    Athens

  • Research Site 202

    Athens

  • Research Site 205

    Athens

  • Research Site 207

    Athens

  • Reserach Site 206

    Athens

  • Research Site 198

    Heraklion

  • Research Site 204

    Ioannina

  • Research Site 192

    Larissa

  • Research Site 199

    Marousi

  • Research Site 191

    Pátrai

  • Research Site 203

    Pátrai

  • Research Site 195

    Thessaloniki

Other trials in Greece

Germany14 sites
  • Research Site 172

    Augsburg

  • Research Site 177

    Berlin

  • Research Site 180

    Berlin

  • Research Site 178

    Bonn

  • Research Site 179

    Cologne

  • Research Site 184

    Dresden

  • Research Site 174

    Hamburg

  • Research Site 182

    Heidelberg

  • Research Site 181

    Leipzig

  • Research Site 173

    Mainz

  • Research Site 176

    Minden

  • Research Site 171

    Regensburg

  • Research Site 183

    Rostock

  • Research Site 175

    Tübingen

Other trials in Germany

Turkey (Türkiye)13 sites
  • Research Site 538

    Ankara

  • Research Site 544

    Ankara

  • Research Site 531

    Istanbul

  • Research Site 534

    Istanbul

  • Research Site 536

    Istanbul

  • Research Site 541

    Istanbul

  • Research Site 543

    Istanbul

  • Research Site 539

    Izmir

  • Research Site 533

    Kocaeli

  • Research Site 537

    Konya

  • Research Site 540

    Mersin

  • Research Site 535

    Samsun

  • Research Site 532

    Trabzon

Other trials in Turkey (Türkiye)

Italy12 sites
  • Research Site 218

    Bari

  • Research Site 216

    Catania

  • Research Site 214

    Cefalù

  • Research Site 219

    Florence

  • Research Site 221

    Milan

  • Research Site 211

    Naples

  • Research Site 215

    Naples

  • Research Site 220

    Orbassano

  • Research Site 217

    Palermo

  • Research Site 212

    Pozzilli

  • Research Site 213

    Roma

  • Research Site 222

    Roma

Other trials in Italy

Spain12 sites
  • Research Site 384

    Alcorcón

  • Research Site 391

    Barakaldo

  • Research Site 390

    Barcelona

  • Research Site 382

    Córdoba

  • Research Site 389

    El Palmar

  • Research Site 388

    Madrid

  • Research Site 392

    Majadahonda

  • Research Site 383

    Málaga

  • Research Site 387

    Seville

  • Research Site 385

    Valencia

  • Research Site 386

    Valencia

  • Research Site 381

    Vigo

Other trials in Spain

Portugal11 sites
  • Research Site 293

    Aveiro

  • Research Site 282

    Braga

  • Research Site 289

    Coimbra

  • Research Site 281

    Lisbon

  • Research Site 283

    Lisbon

  • Research Site 287

    Lisbon

  • Research SIte 284

    Matosinhos Municipality

  • Research Site 292

    Porto

  • Research Site 288

    Pragal

  • Research Site 291

    Santa Maria da Feira

  • Research Site 286

    Torres Vedras

Other trials in Portugal

Brazil9 sites
  • Research Site 603

    Belo Horizonte

  • Research Site 599

    Curitiba

  • Research Site 604

    Goiânia

  • Research Site 600

    Joinville

  • Research Site 614

    Passo Fundo

  • Research Site 591

    Porto Alegre

  • Research Site 594

    Porto Alegre

  • Research Site 596

    Porto Alegre

  • Research Site 609

    Vitória

Other trials in Brazil

France9 sites
  • Research Site 455

    Bordeaux

  • Research Site 459

    Brest

  • Reserach Site 451

    Clermont-Ferrand

  • Research Site 458

    Limoges

  • Research Site 456

    Nîmes

  • Research Site 453

    Paris

  • Research Site 457

    Pringy

  • Research Site 452

    Strasbourg

  • Research Site 454

    Tours

Other trials in France

Slovakia8 sites
  • Research Site 351

    Banská Bystrica

  • Research Site 352

    Bratislava

  • Research Site 353

    Bratislava

  • Research Site 354

    Bratislava

  • Research Site 356

    Bratislava

  • Research Site 359

    Dubnica nad Váhom

  • Research Site 358

    Trenčín

  • Research Site 357

    Trnava

Other trials in Slovakia

Belarus5 sites
  • Research Site 143

    Grodno

  • Research Site 144

    Homyel

  • Research Site 142

    Minsk

  • Research Site 141

    Vitebsk

  • Research Site 145

    Vitebsk

Other trials in Belarus

Malaysia5 sites
  • Research Site 551

    Kuala Lumpur

  • Research Site 554

    Kuala Lumpur

  • Research Site 556

    Kuala Lumpur

  • Research Site 552

    Kuching

  • Research Site 553

    Seberang Jaya

Other trials in Malaysia

Canada4 sites
  • Research Site 106

    Burnaby

  • Research Site 107

    London

  • Research Site 105

    Montreal

  • Research Site 101

    Ottawa

Other trials in Canada

India4 sites
  • Research Site 445

    Ahmedabad

  • Research Site 444

    Bangalore

  • Research Site 443

    Mangalore

  • Research Site 442

    New Delhi

Other trials in India

Lithuania4 sites
  • Research site 241

    Kaunas

  • Research site 244

    Klaipėda

  • Research site 243

    Šiauliai

  • Research site 242

    Vilnius

Other trials in Lithuania

Romania4 sites
  • Research Site 314

    Brasov

  • Research Site 307

    Bucharest

  • Research Site 309

    Caracal

  • Research Site 302

    Târgu Mureş

Other trials in Romania

South Africa4 sites
  • Research Site 501

    Cape Town

  • Research Site 502

    Cape Town

  • Research Site 503

    Cape Town

  • Research Site 504

    Pretoria

Other trials in South Africa

Sweden4 sites
  • Research Site 512

    Gothenburg

  • Research site 514

    Malmö

  • Research Site 511

    Stockholm

  • Research Site 513

    Uppsala

Other trials in Sweden

Latvia3 sites
  • Research Site 231

    Riga

  • Research Site 232

    Riga

  • Research Site 233

    Riga

Other trials in Latvia

Norway3 sites
  • Research Site 481

    Bergen

  • Research site 483

    Drammen

  • Research Site 482

    Namsos

Other trials in Norway

Slovenia3 sites
  • Research Site 373

    Celje

  • Research Site 372

    Ljubljana

  • Research Site 371

    Maribor

Other trials in Slovenia

Switzerland3 sites
  • Research Site 404

    Aarau

  • Research Site 402

    Bern

  • Research Site 403

    Lugano

Other trials in Switzerland

Moldova2 sites
  • Research Site 251

    Chisinau

  • Research Site 252

    Chisinau

Other trials in Moldova

Philippines2 sites
  • Research Site 562

    Baguio City

  • Research Site 561

    Cebu City

Other trials in Philippines

Singapore2 sites
  • Research Site 571

    Singapore

  • Research site 572

    Singapore

Other trials in Singapore

Thailand2 sites
  • Research Site 583

    Bangkoknoi

  • Research Site 582

    Muang

Other trials in Thailand

Puerto Rico1 site
  • Research Site 791

    Guaynabo

Other trials in Puerto Rico

Saudi Arabia1 site
  • Research Site 493

    Riyadh

Other trials in Saudi Arabia

About this study

Official title: A Phase III, Multicenter, Randomized, Parallel Group, Double Blind, Double Dummy, Active Controlled Study of Evobrutinib Compared With Teriflunomide, in Participants With Relapsing Multiple Sclerosis to Evaluate Efficacy and Safety (evolutionRMS 2)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.

Being tested
Teriflunomide, Evobrutinib
Keywords
Evobrutinib, Teriflunomide, Aubagio®, Relapsing Multiple Sclerosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • TeriflunomideDrug

    Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period.

  • EvobrutinibDrug

    Also called M2951

    Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period.

Study groups in NCT04338061
Study groupRoleWhat they receive
TeriflunomideActive comparatorNot described
Receives: Drug: Teriflunomide
EvobrutinibExperimentalNot described
Receives: Drug: Evobrutinib

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)

    The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than [>] 24 hours, no fever, infection, injury, adverse events (AEs), and preceded by a stable or improving neurological state for more than or equal to [>=] 30 days).

    Measured: Baseline up to 170 weeks

Secondary outcomes (31)
  1. DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

    Disability progression was defined as increase in EDSS of greater than or equal to [>=] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of >=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 12 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 12-week CDP.

    Measured: Week 96 and Week 156 (combined DBTP and DBE periods)

  2. DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)

    Disability progression was defined as increase in EDSS of greater than or equal to [>=] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of >=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 24-week CDP.

    Measured: Week 96 and Week 156 (combined DBTP and DBE periods)

  3. DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)

    Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is >= 2 and less than or equal to [<=] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is >= 6.5 and <= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants with 12-week CDI.

    Measured: Week 96 and Week 156 (combined DBTP and DBE periods)

  4. DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156

    Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 10 to 65. Higher T-scores represent higher physical function. Change from baseline in PROMIS PF score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

    Measured: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (Combined DBTP and DBE periods)

  5. DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156

    PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Change from baseline in PROMIS fatigue score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).

    Measured: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 ((combined DBTP and DBE periods)

  6. DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions

    Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans.

    Measured: Baseline up to 170 weeks

  7. DBTP and DBE Period: New or Enlarging T2 Lesions Rate

    Analysis of new or enlarging T2 lesions rate was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan.

    Measured: Baseline up to 170 weeks

  8. DBTP Period: Neurofilament Light Chain (NfL) Concentration at Week 12

    NfL is a biomarker of neuro-axonal damage whose concentration was assessed in blood at Week 12.

    Measured: Week 12

  9. DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)

    Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: those AEs with an onset date on or after the date of first study intervention administration, or AEs present prior to any study intervention administration but exacerbating after. TEAEs included both Serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug-induced, non-infectious, non-alcoholic, and immune-mediated), infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.

    Measured: Baseline up to 170 weeks

  10. DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity

    Severity of adverse events (AE) were assessed by the investigator per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with Grades 1, 2, 3, 4 and 5 were reported.

    Measured: Baseline up to 170 weeks

  11. DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure

    Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: diastolic blood pressure and systolic blood pressure from baseline up to 170 weeks were reported.

    Measured: Baseline up to 170 weeks

  12. DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate

    Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: pulse rate from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  13. DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate

    Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: respiratory rate from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  14. DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight

    Changes in vital signs: weight from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  15. DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature

    Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: Temperature from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  16. DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): Heart Rate

    Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: heart rate from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  17. DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs): QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration

    QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration from baseline up to 170 weeks were reported.

    Measured: Baseline up to 170 weeks

  18. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin. Changes in hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin from baseline up to 170 weeks were reported.

    Measured: Baseline up to 170 weeks

  19. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes. Changes in hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes from baseline up to 170 weeks were reported.

    Measured: Baseline up to 170 weeks

  20. DBTP and DBE Periods: Change From Baseline in Hematology Parameters: Hematocrit

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Hematocrit. Changes in hematology parameter: Hematocrit from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  21. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Changes in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  22. DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Changes in hematology parameter: Erythrocytes Mean Corpuscular Volume from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  23. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Bilirubin and Creatinine. Changes in biochemistry parameters: Bilirubin and Creatinine from baseline up to 170 weeks were reported.

    Measured: Baseline up to 170 weeks

  24. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase. Changes in biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase from baseline up to 170 weeks were reported.

    Measured: Baseline up to 170 weeks

  25. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium. Changes in biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium from baseline up to 170 weeks were reported.

    Measured: Baseline up to 170 weeks

  26. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Total Protein and Albumin. Changes in biochemistry parameters: Total Protein and Albumin from baseline up to 170 weeks were reported.

    Measured: Baseline up to 170 weeks

  27. DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Glomerular Filtration Rate

    Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameter: Glomerular Filtration Rate. Changes in biochemistry parameter: Glomerular Filtration Rate from baseline up to 170 weeks were reported. The Glomerular Filtration Rate was measured as milliliter per minute per 1.73 square meter (mL/min/1.73m^2).

    Measured: Baseline up to 170 weeks

  28. DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine

    Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: pH. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Changes in urinalyses parameter: pH from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  29. DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine

    Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: Specific Gravity of Urine. Changes in urinalyses parameter: Specific Gravity of Urine from baseline up to 170 weeks was reported.

    Measured: Baseline up to 170 weeks

  30. DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels

    Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.

    Measured: At Week 170

  31. DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels

    Change from baseline serum levels of IgG, IgA, IgM were assessed.

    Measured: Baseline up to 170 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Apr 2020
  2. Study start2 Jul 2020
  3. Primary completion2 Oct 2023
  4. Study completion19 Mar 2024

Why it stopped: Primary analysis of the RMS phase 3 study (MS200527\_0082) resulted in the early termination of the study.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
1,166 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04338061
Sponsor's protocol ID
MS200527_0082
Other IDs
2019-004980-36, 2019
Status last verified
Mar 2025
First submitted
6 Apr 2020
Last updated
21 Mar 2025
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

Publications

  • Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19.

    PubMed 39307151

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Teriflunomide and Evobrutinib in people with Relapsing Multiple Sclerosis, run by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany at 278 sites in 32 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 21 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 278 sites in United States, Russia, Ukraine, Poland, Bulgaria and 27 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 14 Jan 2025). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR) (time frame: Baseline up to 170 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04338061, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Mar 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in